Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011977 | 1.00 | MEN1 (0.59) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL14990788 | 1.00 | MEN1 (0.59) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL677191 | 0.85 | MEN1 (0.59) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL2953275 | 0.85 | KMT2A (0.55) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL2796816 | 0.85 | KMT2A (0.55) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL16403677 | 0.85 | MEN1 (0.51) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL2953278 | 0.85 | KMT2A (0.55) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL7996485 | 0.84 | MEN1 (0.57) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL1547478 | 0.84 | MEN1 (0.57) | MEN1KMT2ALMNAALDH1A1POLB | |
| SCHEMBL401056 | 0.84 | MEN1 (0.57) | MEN1KMT2ALMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937176-B2 | Pyrazolothiazole compound and medicine comprising same | NIPPON SHINYAKU CO., LTD. (JP) | 2018-04-10 | — | — | US | disclosed |
| US-20170252341-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-9540344-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9045460-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2015-03-26 | — | — | US | disclosed |
| EP-2818463-A1 | Production method of 1,4-diazepane derivatives | Kowa Co., Ltd. (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2610252-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | Kowa Co., Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | MEN1 2569/4885KMT2A 4399/4885LMNA 3679/4885 |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | CS, CYP11B1, GPR119 | MEN1 1098/4885KMT2A 2657/4885LMNA 705/4885 |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | MEN1 2569/4885KMT2A 4399/4885LMNA 3679/4885 |
| US-20170252341-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | JAK1, JAK2, JAK3 | MEN1 1734/4885KMT2A 3230/4885LMNA 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.